Literature DB >> 27005482

Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma.

Y-Y Wang1, J-H Zhong1,2, Z-Y Su3, J-F Huang3, S-D Lu1, B-D Xiang1,2, L Ma1,2, L-N Qi1,2, B-N Ou3, L-Q Li1,2.   

Abstract

BACKGROUND: The Child-Pugh (CP) score is used widely to assess liver function and predict postoperative outcomes in patients with hepatocellular carcinoma (HCC). Recently, the albumin-bilirubin (ALBI) score has been validated as a predictor of overall survival in these patients. This study aimed to compare the ability of the ALBI and CP scores to predict outcomes in patients with HCC after liver resection with curative intent.
METHODS: Consecutive patients who underwent liver resection with curative intent for HCC between January 2007 and July 2013 were included in this retrospective study. The performance of the ALBI score in predicting postoperative liver failure (PHLF) and long-term survival was compared with that of the CP score.
RESULTS: A total of 1242 patients were enrolled. Of these, 166 (13·4 per cent) experienced PHLF. The area under the receiver operating characteristic (ROC) curve of the ALBI score for predicting PHLF was greater than that of the CP score (0·723 versus 0·607; P < 0·001). Similar to findings for CP grade, the incidence and severity of PHLF increased with increasing ALBI grade. The ALBI grade stratified patients into at least two distinct overall survival cohorts (P < 0·001), whereas the CP grade did not. The ALBI grade also classified patients with CP grade A disease into two distinct overall survival cohorts (P < 0·001), and overall survival rates in the group with poorer survival were similar to those in the majority of patients with CP grade B disease. Both CP and ALBI scores had low power in predicting disease-free survival.
CONCLUSION: The ALBI grade predicted PHLF and overall survival in patients with HCC undergoing liver resection with curative intent more accurately than the CP grade.
© 2016 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27005482     DOI: 10.1002/bjs.10095

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  96 in total

1.  Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2017-03-09       Impact factor: 11.740

2.  Postoperative Albumin-Bilirubin Grade Change Predicts the Prognosis of Patients with Hepatitis B-Related Hepatocellular Carcinoma Within the Milan Criteria.

Authors:  Chuan Li; Xiao-Yun Zhang; Wei Peng; Tian-Fu Wen; Lu-Nan Yan; Bo Li; Jia-Yin Yang; Wen-Tao Wang; Ming-Qing Xu
Journal:  World J Surg       Date:  2018-06       Impact factor: 3.352

3.  Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications.

Authors:  Atsushi Hiraoka; Takashi Kumada; Masatoshi Kudo; Masashi Hirooka; Kunihiko Tsuji; Ei Itobayashi; Kazuya Kariyama; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Kouji Joko; Hideki Kawasaki; Yoichi Hiasa; Kojiro Michitaka
Journal:  Liver Cancer       Date:  2017-03-09       Impact factor: 11.740

4.  Preoperative prediction for pathological grade of hepatocellular carcinoma via machine learning-based radiomics.

Authors:  Bing Mao; Lianzhong Zhang; Peigang Ning; Feng Ding; Fatian Wu; Gary Lu; Yayuan Geng; Jingdong Ma
Journal:  Eur Radiol       Date:  2020-07-22       Impact factor: 5.315

5.  Pre-transplant ALBI Grade 3 Is Associated with Increased Mortality After Liver Transplantation.

Authors:  Nicole Bernardi; Marcio F Chedid; Tomaz J M Grezzana-Filho; Aljamir D Chedid; Marcelo A Pinto; Ian Leipnitz; João E Prediger; Carolina Prediger; Ariane N Backes; Thais O Hammes; Lea T Guerra; Alexandre de Araujo; Mario R Alvares-da-Silva; Cleber R P Kruel
Journal:  Dig Dis Sci       Date:  2019-01-14       Impact factor: 3.199

Review 6.  Diagnosis, Staging, and Patient Selection for Locoregional Therapy to Treat Hepatocellular Carcinoma.

Authors:  Zachary T Berman; Isabel Newton
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

7.  Albumin-Bilirubin Score: Predicting Short-Term Outcomes Including Bile Leak and Post-hepatectomy Liver Failure Following Hepatic Resection.

Authors:  Nikolaos Andreatos; Neda Amini; Faiz Gani; Georgios A Margonis; Kazunari Sasaki; Vanessa M Thompson; David J Bentrem; Bruce L Hall; Henry A Pitt; Ana Wilson; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2016-09-12       Impact factor: 3.452

8.  Combined Preoperative ALBI and FIB-4 Is Associated with Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy.

Authors:  Rui Liao; De-Wei Li; Cheng-You Du; Ming Li
Journal:  J Gastrointest Surg       Date:  2018-05-18       Impact factor: 3.452

9.  Value of the albumin-bilirubin score in the evaluation of hepatitis B virus-related acute-on-chronic liver failure, liver cirrhosis, and hepatocellular carcinoma.

Authors:  Qing Lei; Yinhua Zhang; Changzheng Ke; Chunchun Yan; Ping Huang; Haixia Shen; Huiting Lei; Yue Chen; Jie Luo; Zhongji Meng
Journal:  Exp Ther Med       Date:  2018-01-12       Impact factor: 2.447

10.  Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation.

Authors:  In Soo Oh; Dong Hyun Sinn; Tae Wook Kang; Min Woo Lee; Wonseok Kang; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik
Journal:  Dig Dis Sci       Date:  2017-10-05       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.